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Background. Apical Membrane Antigen 1 (AMA1) of Plasmodium falciparum merozoites is a leading blood-stage malaria
vaccine candidate. Protection of Aotus monkeys after vaccination with AMA1 correlates with antibody responses. Study
Design/Results. A randomized, controlled, double-blind phase 1 clinical trial was conducted in 54 healthy Malian adults
living in an area of intense seasonal malaria transmission to assess the safety and immunogenicity of the AMA1-C1 malaria
vaccine. AMA1-C1 contains an equal mixture of yeast-expressed recombinant proteins based on sequences from the FVO
and 3D7 clones of P. falciparum, adsorbed on Alhydrogel. The control vaccine was the hepatitis B vaccine (Recombivax).
Participants were enrolled into 1 of 3 dose cohorts (n=18 per cohort) and randomized 2:1 to receive either AMA1-C1 or
Recombivax. Participants in the first, second, and third cohorts randomized to receive AMA1-C1 were vaccinated with 5, 20
and 80 mg of AMA1-C1, respectively. Vaccinations were administered on days 0, 28, and 360, and participants were followed
until 6 months after the final vaccination. AMA1-C1 was well tolerated; no vaccine-related severe or serious adverse events
were observed. AMA1 antibody responses to the 80 mg dose increased rapidly from baseline levels by days 14 and 28 after
the first vaccination and continued to increase after the second vaccination. After a peak 14 days following the second
vaccination, antibody levels decreased to baseline levels one year later at the time of the third vaccination that induced
little or no increase in antibody levels. Conclusions. Although the AMA1-C1 vaccine candidate was well-tolerated and
induced antibody responses to both vaccine and non-vaccine alleles, the antibody response after a third dose given at one
year was lower than the response to the initial vaccinations. Additionally, post-vaccination increases in anti-AMA1 antibody
levels were not associated with significant changes in in vitro growth inhibition of P. falciparum. Trial Registration.
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INTRODUCTION
Due to the limited number of drugs available for treatment of
Plasmodium falciparum malaria and increasing drug resistance,
development of a malaria vaccine has become a global health
priority. A vaccine is considered feasible given that individuals
repeatedly exposed to the parasite gradually develop immunity to
the clinical manifestations of infection. This resistance to clinical
disease is partly mediated by antibodies to antigens expressed
during the asexual blood stages of the P. falciparum life cycle [1,2].
One such protein, the apical membrane antigen 1 (AMA1), has
been shown to play a significant role in erythrocyte invasion [3–6].
Vaccination with recombinant AMA1 induces protection
against homologous parasite challenge in both rodents and
monkeys [7–11]. Due to the strain-specificity in antibody
responses to AMA1 [9] and the sequence polymorphism of the
AMA1 gene that exists among circulating strains of P. falciparum
[12–14], the AMA1-C1 vaccine was designed as an equal mixture
of the recombinant AMA1 proteins derived from the FVO and
3D7 clones of P. falciparum, in an attempt to induce protective
immunity against diverse parasite strains present in endemic areas.
In a Phase 1 study of the AMA1-C1 vaccine adjuvanted with
Alhydrogel conducted in malaria-naı ¨ve adults living in the United
States, this vaccine was well-tolerated and elicited antigen-specific
antibodies with biological activity against malaria parasites as
judged by an in vitro growth inhibition assay (GIA) [15]. Greater
antibody responses were seen after the third vaccination than after
the first two vaccinations. No significant difference was observed in
the antibody responses to the two highest dose concentrations
tested (20 and 80 mg), although both were significantly higher than
the lowest dose tested (5 mg), suggesting that a maximum response
had been attained in this study population.
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1045Due to these promising results, a clinical trial of the AMA1-C1
vaccine was performed in Mali, West Africa. The results of this
study demonstrate that the AMA1-C1/Alhydrogel vaccine induces
a significant humoral immune response in malaria-exposed
individuals even after a single dose of vaccine that increases after
a second vaccination given one month following the first.
Surprisingly, administration of a third vaccination one year
following the initial vaccinations did not result in increased
antibody levels similar to those seen after the first two vaccinations.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Site
The study was conducted in Done ´gue ´bougou, Mali, at a clinic
operated by the Malaria Research and Training Center of the
University of Bamako. Done ´gue ´bougou is a rural village of
approximately 1300 inhabitants in which malaria transmission
occurs mainly during the rainy season extending from June to
November. Entomologic inoculation rates (EIR) as determined by
the human landing catch method vary between zero in the dry
season and 50 to 60 infective bites/person/month at the height of
the rainy season in September and October [16].
The study was approved by the institutional review boards of
the University of Bamako and the US National Institute of Allergy
and Infectious Diseases, and was conducted under an investiga-
tional new drug application (BB-10944) to the US Food and Drug
Administration.
Participants
After obtaining permission from the village elders to conduct the
study, 54 participants were enrolled into 1 of 3 cohorts. Written
informed consent was obtained from healthy volunteers between
the ages of 18 and 45 years. Volunteers were excluded if they had
evidence of clinically significant systemic disease; were pregnant or
breast feeding; had serological evidence of chronic hepatitis B or C
infection; were receiving corticosteroids or immunosuppressive
drugs; or had been immunized with a live vaccine within the
previous month.
Interventions
Recombinant AMA1-FVO and AMA1-3D7 were manufactured,
mixed, and adsorbed to Alhydrogel (HCl Biosector) as described
previously [9]. Each 0.5 mL dose contained either 5, 20, or 80 mg
AMA1-C1 and 800 mg Alhydrogel. Potency studies in mice
conducted every 6 months confirmed that all lots were stable
and potent throughout the trial. Recombivax HB (Merck&Co.)
was supplied in single-dose vials containing 10 mg of recombinant
hepatitis B surface antigen adsorbed to amorphous aluminum
hydroxyphosphate sulfate at a final volume of 1.0 mL. Vaccines
were transported to the study site using temperature monitoring
devices to ensure maintenance of the cold chain.
Within each cohort, participants were randomized to receive
either AMA1-C1/Alhydrogel (n=12) or Recombivax (n=6), with
the first, second, and third cohorts enrolled successively at three-
week intervals. Participants randomized to AMA1-C1 received 5,
20 and 80 mg in the first, second, and third cohorts, respectively.
Vaccinations were administered by intramuscular injection in the
deltoid muscle on study days 0, 28, and 360.
The safety of study participants was monitored throughout the
trial by an independent Malian physician. Interim safety reports
were reviewed by a data and safety monitoring board prior to
vaccination of the second and third cohorts, and before
administration of the third vaccinations on study day 360.
Objectives
The primary objective was to estimate the frequency of vaccine-
related adverse events, graded by severity, for each dose of AMA1-
C1 being tested. Secondary objectives included evaluation of the
allele-specific antibody response to vaccination, assessment and
comparison of the duration of antibody response to AMA1-FVO
and AMA1-3D7, measurement of the inhibition of parasite growth
as measured by the in vitro GIA to the FVO and 3D7 clones of P.
falciparum, and determination of the relationship between anti-
AMA1 antibody concentration, as judged by ELISA, and degree
of in vitro growth inhibition of P. falciparum by GIA.
Outcomes
Following vaccinations, volunteers were directly observed for
30 minutes and then evaluated 1, 2, 3, 7, and 14 days post-
vaccination for evidence of local and systemic reactogenicity, and
then monthly throughout the malaria transmission seasons
following the second and third vaccinations until the end of the
study approximately 6 months after the third vaccination. In-
jection sites were examined for erythema, swelling, and tenderness
at the site of injection. Solicited systemic adverse events included
fever or chills, headache, nausea, myalgia, and arthralgia. Adverse
events were graded as either mild (easily tolerated), moderate
(interfered with activities of daily living), or severe (prevented
activities of daily living), and assigned causality relative to the study
vaccine. Injection site erythema and swelling were graded as mild
(.0t o#20 mm in diameter), moderate (.20 to #50 mm), or
severe (.50 mm). Oral temperature was graded as mild (.37.5uC
to#38.0uC), moderate (.38.0uCt o #39.0uC), or severe
(.39.0uC). A complete blood count, serum creatinine and alanine
aminotransferase concentration were performed immediately prior
to each vaccination as well on the third and fourteenth days
following vaccination. Complete blood counts were also per-
formed at the monthly visits during the malaria transmission
seasons of each study year.
Anti-AMA1 antibodies were measured using a standardized
ELISA [15]. ELISA plates were coated with AMA1-FVO, AMA1-
3D7, or AMA1-L32, a P. pastoris-expressed recombinant protein
based on the sequence of the L32 strain of P. falciparum (Genbank
accession number EF221749) and that differs from the FVO and
3D7 antigens by 26 and 24 amino acids, respectively. Serial dilutions
ofa standardserumpoolwereincludedoneachtestplate togenerate
a standard curve, which was used to convert the absorbance of
individual sera into antibody units. Participant samples from days
0 to 180 and from days 270 to 540 were tested at separate times.
Antigen-specific IgG subclasses were measured by a flow
cytometric suspension array assay. Serum samples were mixed
with microspheres coupled to AMA1 (Luminex Corporation).
Mouse anti-human IgG subclass antibodies (anti-human IgG1,
IgG2, IgG3, and IgG4) and a secondary donkey anti-mouse IgG
phycoerythrin-labeled antibody (Jackson ImmunoResearch) were
added to develop the reactions. Mean fluorescence intensities were
detected by Luminex X-MAP using Bioplex software (BioRad).
IgG from vaccinated individuals were tested for their ability to
inhibit in vitro growth of P. falciparum 3D7 and FVO parasites using
a standardized GIA procedure [15,17]. Values obtained with test
samples were compared to those obtained from parasites in-
cubated with a pool of malaria-naı ¨ve human serum and with
uninfected red cells to obtain the percent inhibition in growth.
AMA1 Vaccine in Malian Adults
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Although not powered to detect differences in the incidence of
specific adverse events or immune responses between AMA1-C1
and Recombivax or between the different dose concentrations of
AMA1-C1, a group size of 12 per dose concentration of AMA1-
C1 was chosen to give a reasonable probability of detecting one or
more serious or severe vaccine-related adverse events. A group size
of 10 individuals would provide a power of 80% to detect an
adverse event that occurs with a probability of 0.15; an extra 2
participants were recruited into each group in case of withdrawal
or loss to follow-up.
In addition, each dose concentration of AMA1-C1 was
compared to Recombivax, which served as a comparison for both
immunologic and safety assessments. A total of 18 controls, 6 per
each dose concentration of AMA1-C1, were enrolled to allow a 2:1
ratio of AMA1-C1 to Recombivax within each cohort; thus, each
of the 3 cohorts contained 12 volunteers receiving AMA1-C1 plus
6 receiving Recombivax for a total sample size of 54.
Randomization
Within each cohort, participants were randomized to receive
either AMA1-C1 or Recombivax by use of sealed envelopes
labeled with a unique participant study number and containing
the vaccine assignment. A set of 18 envelopes were prepared for
each cohort such that 12 contained assignments to AMA1-C1 and
6 to Recombivax. Study numbers were assigned in the order that
participants arrived at the clinic on the day of first immunization.
Randomization envelopes were opened by a study pharmacist on
the day of first immunization and immediately re-sealed after
vaccine assignment.
Blinding
Study participants and investigators who assessed outcomes were
blinded to vaccine assignment. Access to randomization codes was
limited to the study pharmacists. Syringe barrels were masked with
opaque tape to disguise the contents, since the volumes of the two
study vaccines were different. To reduce investigator bias,
injections were administered by physicians who were not involved
in post-vaccination safety assessments or study analysis.
Statistical Methods
Differences in the proportion of individuals experiencing each
adverse event (of any severity) between vaccine allocations
(AMA1-C1 vs. Recombivax) and between vaccinations (first versus
second, etc.) within each dose group were analyzed using Fisher’s
exact and McNemar’s tests, respectively. The exact two-sided
Cochrane-Armitage test for trend using rank scores was used to
test for a dose effect for each solicited adverse event; for these
analyses, the Recombivax group was assigned a dose of 0 mgo f
AMA1-C1.
Differences in the change in antibody level from baseline to
post-vaccination time points were compared between AMA1-C1
and Recombivax using exact Wilcoxon rank sum tests within each
cohort. Differences in change of antibody (days 0 and 42) between
dose groups were analyzed using the two-sided Wilcoxon rank sum
test, assuming the absence of an effect due to differing vaccination
times for the cohorts in relation to the malaria transmission season
(this assumption was not violated by a Kruskal-Wallis test for
cohort effect on day 0 values [p.0.4]). Agreements between anti-
AMA1-FVO, anti-AMA1-3D7, and anti-AMA1-L32 antibody
responses were calculated using the random marginal agreement
coefficient (RMAC) with the squared difference cost [18].
Correlations between percent growth inhibition and antibody
responses were assessed by the Spearman rank test. The SAS
(version 9.1; SAS), R (version 2.4.0; R Foundation for Statistical
Computing) and STATA (version 8.0; StataCorp) software
packages were used, and p,.05 was considered significant.
RESULTS
Participant Flow and Baseline Data
One hundred and nine adults were screened for inclusion in the
study, of whom 54 (45 males and 9 females) were enrolled
(Figure 1). Reasons for exclusion were concurrent illness (n=22),
positive serology for chronic hepatitis B or C (n=18), other
abnormal screening laboratory tests (n=9), intent to travel during
the study period (n=1), and history of significant allergy (n=3);
two volunteers were eligible but not enrolled.
The median age of participants was 30 years (range, 18 to 45).
Vaccinations were initiated in May 2004; all cohorts received their
second vaccination by the end of July 2004 before the onset of
significant malaria transmission. The third vaccinations were
administered in May and June 2005, immediately prior to the
onset of that year’s malaria transmission season. One subject,
randomized to receive 20 mg of AMA1-C1/Alhydrogel was
withdrawn after the first vaccination: this participant was anti-
HCV antibody positive at screening but was inadvertently enrolled
and received the first dose of vaccine before the error was
discovered. Data from this subject were included in the safety but
not the immunogenicity analyses. All other participants received
all planned vaccinations and completed all scheduled study visits,
and were included in all analyses.
Safety
All vaccinations were well tolerated (Table 1). Mild pain and
swelling were the most commonly observed injection site reactions,
and there were no significant differences among the proportions of
volunteers with these reactions between vaccines (AMA1-C1 vs.
Recombivax) or between vaccinations within dose groups.
Similarly, there was no dose response in the occurrence of
injection site reactions except for injection site swelling after the
first vaccination which occurred more frequently with increasing
dose concentrations of AMA1-C1 (p=0.03) . Solicited systemic
reactions were uncommon, with mild to moderate headache being
the most frequently observed event. There were no significant
differences between AMA1-C1 and Recombivax or between
successive vaccinations within dose groups, and no dose-response,
in the incidence of systemic reactions.
No serious adverse events, hypersensitivity reactions, or clinical
laboratory abnormalities occurred that were related to vaccination
with AMA1-C1/Alhydrogel.
IgG responses to AMA1-3D7 and AMA1-FVO
Prior to vaccination, antibodies to both AMA1-FVO and AMA1-
3D7 were detectable in sera of individuals from all cohorts
(Figure 2a). There was a highly significant concordance between
the antibody responses to AMA1-FVO and AMA1-3D7 both
before vaccination (RMAC, 0.97 [95% confidence interval {CI},
0.95–0.98]; Figure 2a) and after vaccination (RMAC, 0.96 [95%
CI, 0.94–0.98]; Figure 2b). Because of the high concordance
between ELISA values for the two AMA1 antigens, data are only
presented for AMA1-3D7. In all cases, similar data were observed
for AMA1-FVO.
There was a significant increase in antibody response from
baseline to day 42 (14 days after the second vaccination) in both
the 20 mg (median increase of 381 ELISA units; p=0.01) and
80 mg (median increase of 1554 ELISA units; p=0.007) groups
AMA1 Vaccine in Malian Adults
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80 mg group displaying a greater increase in antibodies to AMA1
than the 20 mg group (p=0.03). However, 3 of 12 volunteers in the
80 mg group had a poor antibody response after the first two
vaccinations (increases of 219 to 321 ELISA units; Table 2). The
IgG subclass distribution for the AMA1 antibodies was unchanged
by vaccination with AMA1-C1, and was comprised mostly of IgG1
and IgG3.
The increase in AMA1-specific antibodies following the first
vaccination with 80 mg of AMA1 was rapid and already apparent
by day 14, consistent with boosting a memory response (Figure 4).
To explore the effect of pre-existing antibody levels on the
response to vaccination, the change in anti-AMA1 antibody levels
was compared to pre-vaccination antibody levels (Figure 5). For
the 80 mg AMA1-C1 group, there was a significant positive
correlation between anti-AMA1 antibody levels on day 0 and the
increase in antibody between days 0 and 42 (Spearman rank
correlation, 0.66, p=0.02; Figure 5).
After a peak in antibody levels two weeks following the second
vaccination, anti-AMA1 antibody responses in the 80 mg AMA1-
C1 dose group declined halfway to baseline by day 90 and
returned to baseline by day 360, the day of the third vaccination
(Figure 4). Participants were re-vaccinated approximately one year
after the first two vaccinations and just prior to the start of the
malaria transmission season. Following this third vaccination,
a significant increase in anti-AMA1 antibody level was seen only in
the 80 mg AMA1-C1 group when compared to Recombivax
(p=0.003), although the magnitude of this response was much
lower than was seen after the first two vaccinations (Figure 3b): the
median increase was only 185 ELISA units. Remarkably, the 7
Figure 1. CONSORT Flow Chart.
doi:10.1371/journal.pone.0001045.g001
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vaccinations showed little or no response (i.e., less than 1000
ELISA units) to the third vaccination (Table 2). Furthermore, two
volunteers (#40 and #53) who had high antibody levels after the
second vaccination had no rise in antibody after the third
vaccination (Table 2). Those who did not have appreciable
responses after the first 2 vaccinations also did not respond to the
third vaccination. There was no evidence of general immune
suppression in the Malian volunteers because the third vaccination
with Recombivax induced the expected rise in antibody levels to
hepatitis B surface antigen (data not shown).
IgG responses to AMA1-L32
To determine whether antibodies induced by vaccination would
cross-react with other allelic variants of AMA1, antibodies to
AMA1-L32 were assessed by ELISA. Two weeks after the second
vaccination, antibody responses to AMA1-L32 increased signifi-
cantly from baseline by a median of 533 ELISA units (p=0.0004)
in participants who received 80 mg AMA1-C1 compared to no
increase in those receiving Recombivax. The increase in antibody
to AMA1-L32 was lower than to AMA1-3D7 but the responses to
the two alleles were still concordant (RMAC, 0.46 [95% CI, 0.34–
0.56]).
Table 1. Solicited local injection site and systemic adverse events after vaccination with the AMA1-C1/Alhydrogel or Recombivax
HB hepatitis B vaccines.
..................................................................................................................................................
Vaccination#1 Vaccination#2 Vaccination#3
AMA1-C1
Recombivax
(n=18) AMA1-C1
Recombivax
(n=18) AMA1-C1
Recombivax
(n=18)
5 mg
(n=12)
20 mg
(n=12)
80 mg
(n=12)
5 mg
(n=12)
20 mg
(n=11)
80 mg
(n=12)
5 mg
(n=12)
20 mg
(n=11)
80 mg
(n=12)
Local
P a i n 3153 3323 0 4 4 3
Swelling 1463 5459 3 1 1 5
Erythema 0100 0001 0 0 0 0
Systemic
Fever 2001 0000 0 1 0 0
H e a d a c h e 2104 0122 1 1 1 0
N a u s e a 0001 0000 0 0 0 1
Myalgia 0100 0000 0 0 0 0
Arthralgia 0000 0000 0 1 0 0
Data are number of study participants. All injection site reactions were mild whereas systemic reactions were either mild or moderate in intensity.
doi:10.1371/journal.pone.0001045.t001
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Figure 2. Comparison of pre-vaccination (A) and post-vaccination (B) antibody responses to AMA1-3D7 and AMA1-FVO. Sera collected on day
0 and 42 were assayed from all study participants. Concordance between the responses to the 3D7 and FVO alleles of AMA1 were highly significant
on both days (RMAC, 0.97 on day 0 and 0.96 on day 42)
doi:10.1371/journal.pone.0001045.g002
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Pre-vaccination IgG showed growth inhibition ranging from 24%
to 67% for P. falciparum 3D7 (results for the 80 mg AMA1-C1 and
Recombivax groups are given in Table 3). Overall, there was
a statistically significant correlation between pre-vaccination anti-
AMA1 antibody levels and percent growth inhibition of the 3D7
clone (Spearman rank correlation, 0.60; p,0.0001).
Following the second vaccination, no significant change in the
growth inhibition of either P. falciparum 3D7 or FVO was achieved
with any of the doses of AMA1-C1/Alhydrogel or Recombivax
(Table 3). Additionally, among those receiving AMA1-C1, there
was no statistically significant correlation between change (day
0 and 42) in percent growth inhibition and change in anti-AMA1
ELISA units in the IgG purified for the GIA (Spearman rank
correlation, 20.06; p=0.7). To investigate to what extent growth
inhibition observed in individual sera was due to anti-AMA1
antibodies, day 42 samples from four individuals with high levels of
anti-AMA1 antibody (one from each of the AMA1-C1 dose groups
and one from the Recombivax group) were pre-incubated with
AMA1 protein; minimal to no reversal of invasion inhibition was
seen (data not shown).
DISCUSSION
Interpretation
The results of this trial indicate that the AMA1-C1 blood-stage
malaria vaccine adjuvanted with Alhydrogel is well-tolerated when
administered to adult malaria-exposed volunteers living in Mali,
Figure 3. Change from baseline in anti-AMA1-3D7 antibody levels after the second and third vaccinations. Differences between study days 0 (day
of vaccination 1) and 42 (14 days post-vaccination 2) (A) and between study days 360 (day of third vaccination) and 374 (14 days post-vaccination 3)
(B) are shown. Bars represent the median change in antibody units against AMA1-3D7; R, Recombivax
doi:10.1371/journal.pone.0001045.g003
Table 2. Change in individual anti-AMA1-3D7 antibody levels
after the second and third vaccinations with 80 mg of AMA1-
C1/Alhydrogel.
......................................................................
Study
Participant
Baseline Anti-AMA1-3D7
Antibody Level (ELISA Units)
Change in anti-AMA1-3D7
Antibody Level (ELISA Units)
Day 0 Day 360 Day 14
a Day 42
a Day 374
b
38 78 157 277 1315 201
45 100 167 161 219 470
48 392 445 4 300 42
41 576 276 798 1793 655
44 670 592 584 698 135
49 815 442 59 868 22
50 1846 1477 1546 4795 716
40 2203 1976 1335 4619 169
37 3430 1366 758 2647 960
54 4182 2696 2605 321 2158
52 5901 3350 1233 5590 761
53 7037 7875 4739 12751 2102
aCompared to antibody level on day 0
bCompared to antibody level on day 360
doi:10.1371/journal.pone.0001045.t002
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and induces significant anti-AMA1 antibody responses in this
population. Significant responses were observed even after
administration of a single 80 mg dose, suggesting that boosting of
pre-existing immunity from prior exposure to natural infection is
possible with this vaccine.
Given that the proposed mechanism of action of blood-stage
malaria vaccines is through production of antibody against
malarial antigens expressed on the surface of merozoites or
infected erythrocytes, an important objective of this study was to
test the ability of the AMA1-C1 vaccine to induce humoral
immune responses in malaria-experienced individuals. Not
surprisingly, pre-existing levels of anti-AMA1 antibodies were
found in most study participants prior to vaccination, likely due to
previous exposure to this antigen by natural infection. While
vaccination with either Recombivax or 5 mg AMA1-C1 induced
no significant increase in anti-AMA1 antibodies, a significant
increase in responses to both AMA1-3D7 and AMA1-FVO was
detectable after just one dose of 80 mg AMA1-C1 in the Malian
volunteers.
However, the antibody response to vaccination with AMA1-
C1 adjuvanted with Alhydrogel in semi-immune Malian adults
differed from that observed in malaria-naı ¨ve adults in the US. In
US volunteers, a recall response was induced upon vaccinating
five months after the second vaccination although minimal levels
of antibody were seen after the first two vaccinations regardless
of dose [15]. In the Malian study, levels of AMA1-specific
antibody increased after the first and second vaccinations in
a dose dependent fashion, suggesting stimulation of antigen
specific memory cells. However, only small increases in antibody
were induced after a third vaccination of Malian adults
administered one year later. Why did Malians who responded
to the first two vaccinations, respond poorly to the third
vaccination?
Figure 4. Longitudinal anti-AMA1 antibody responses in study participants from the first (A), second (B) and third (C) cohorts. Antibody units
were measured by ELISA in sera collected on: day 0 (vaccination 1), day 14 (14 days post-vaccination 1), day 28 (vaccination 2), day 42 (14 days post-
vaccination 2), day 90, day 180, day 270, day 360 (vaccination 3), day 374 (14 days post-vaccination 3), days 420, 480, and 540. Points represent the
geometric mean antibody units against AMA1-3D7, error bars the standard error, and arrows the vaccination time points; TS, transmission season; u,
5 mg AMA1-C1; %,2 0mg AMA1-C1; D,8 0mg AMA1-C1; 6, Recombivax
doi:10.1371/journal.pone.0001045.g004
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potency either through degradation over time or because of
inadequate transportation or storage conditions. However, this is
unlikely, as biannual potency studies of the lots of vaccine used in
this trial demonstrated continued ability to induce antigen-specific
antibodies in animals. Damage during storage or transport is also
unlikely because electronic temperature monitors recorded no
temperature excursions. Furthermore, study participants who
received the Recombivax vaccine, which was transported and
stored in the same shipments, developed significant anti-hepatitis B
surface antigen antibodies after the third vaccination.
The second possibility is that people living in malaria endemic
areas do not generate long-lived B cell memory to AMA1.
Arguing against this is the fact that some volunteers responded
rapidly to the first vaccination with recall-like kinetics, indicating
pre-existing B cell memory to AMA1 due to prior exposure to P.
falciparum. Moreover, the vaccine itself was able to induce and
recall memory B cells in vaccinated individuals living in the US
[15].
What are the possible immunological mechanisms that might
account for this effect? First, the Malian volunteers had naturally
acquired circulating AMA1-specific antibodies prior to vaccination
unlike the US volunteers who had none. It is therefore possible
that immune complex formation in Malians resulted in Fc-
mediated inhibition of B cells via FccIIB receptor, a major
negative regulator of B cell activation and differentiation [19] or
resulted in masking of important B cell epitopes [20]. Second, the
Malian volunteers were exposed to malaria infections following
vaccination, unlike their American counterparts. Data from
a murine malaria model has shown that vaccination with
MSP119, another blood-stage antigen, followed by infection with
P. yoelii, leads to apoptosis of MSP1-specific memory B cells [21].
Consequently, malaria antigen-specific memory B cells may
undergo deletion, possibly through apoptosis, upon repeated
infection with the parasite [21,22]. Clearly, further study of the
development of B cell memory responses to malaria antigens such
as AMA1 is necessary.
Generalizability
In this study, the AMA1-C1 malaria vaccine was well-tolerated
and did not induce significant vaccine-related adverse events in
malaria-exposed adults; however, any successful blood-stage
malaria vaccine will be targeted primarily at infants and young
children living in endemic areas since they bear the brunt of the
morbidity and mortality due to this disease. Additional trials will
therefore be required to establish safety in these age groups prior
to initiation of larger efficacy studies. Furthermore, responses to
vaccination with AMA1-C1 may be quite different in infants and
young children living in endemic areas who have not been exposed
to the antigen to the same extent as the semi-immune adults
enrolled in the current study, especially considering the hypothesis
that pre-existing anti-malarial antibodies might inhibit B cell
activation as described above. Indeed, results from clinical trials of
the RTS,S malaria vaccine indicate that humoral immune
responses are lower in malaria-exposed adults than in malaria-
exposed young children or malaria-naive adults [23–26].
Although there is considerable animal and human data
supporting the development of AMA1 as a vaccine, a potential
complication is the significant sequence polymorphism seen in
strains isolated from different sites around the world. AMA1 has
a minimum of 107 different haplotypes at the amino acid level (J
Mu and LH Miller, unpublished data). Evidence that this
polymorphism might affect vaccine efficacy comes from animal
studies showing that rabbits immunized with one AMA1
haplotype produce antibodies that preferentially recognize homol-
ogous antigen, with reduced responses to heterologous AMA1 [9].
To overcome this potential obstacle to vaccine efficacy, AMA1-C1
incorporates both the 3D7 and FVO alleles of the protein in an
attempt to elicit a broader immune response than that achievable
by vaccination with either component alone. Whether recipients of
the vaccine will be protected against parasites with polymorphic
sequences (e.g., L32) remains to be determined.
In the current study, no association was seen between the
significant increase in anti-AMA1 antibodies after the second
vaccination with the 80 mg dose of AMA1-C1 and change in GIA
activity. There are several potential reasons for this. First, pre-
vaccination sera for most AMA1-C1 recipients displayed signifi-
cant levels of growth inhibition, likely due to antibodies to a host of
P. falciparum antigens induced by prior infections. The presence of
antibodies to non-AMA1 antigens and the small number of
participants in our study make interpretation of these GIA results
difficult. However, preliminary evidence for the in vitro growth
inhibition activity in these individuals being unrelated to antibody
against AMA1 is the finding that in a subset of four post-
vaccination serum samples with high levels of anti-AMA1
antibody, pre-incubation with AMA1 antigen failed to reverse
growth inhibition.
Overall evidence
In the first clinical trial of an AMA1 vaccine in an endemic area,
the AMA1-C1 vaccine was safe when administered to malaria-
exposed adults and, at the highest dose, was able to induce
significant immune responses against the individual vaccine
components as well as against a heterologous AMA1 allele.
Improvements in the vaccine can clearly be made in order to elicit
responses more likely to be sustained and protective, as individuals
in the high-dose group who responded strongly after the first two
vaccinations had minimal or no rise in AMA1-specific antibody
levels after the third vaccination, and induction of antibody failed
to translate into any significant increase in in vitro growth
inhibition of the parasite. Different formulations of this vaccine–
Figure 5. Post-vaccination changes in anti-AMA1-3D7 antibody levels
compared to baseline levels. Change in anti-AMA1-3D7 antibody
levels between study days 0 (day of vaccination 1) and 42 (14 days
post-vaccination 2), are compared to the anti-AMA1-3D7 antibody level
on day 0, in the Recombivax (open circles) and 80 mg AMA1-C1 (black
circles) dose groups
doi:10.1371/journal.pone.0001045.g005
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1045such as the addition of CpG oligodeoxynucleotideates or conjugate
carriers [27,28]–may overcome these limitations and result in
induced antibody responses that are sufficient to impact parasite
replication both in vitro and in vaccinated individuals. AMA1-C1
may nonetheless be a promising blood stage vaccine candidate, but
further evidence is required from additional clinical trials, including
studies conducted in children living in malaria-endemic areas.
SUPPORTING INFORMATION
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001045.s001 (0.11 MB
PDF)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001045.s002 (0.52 MB
PDF)
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Table 3. In vitro growth inhibition of Plasmodium falciparum 3D7 by sera from recipients of Recombivax and 80 mg AMA1-C1/
Alhydrogel.
..................................................................................................................................................
Group Study Participant Anti-AMA1-3D7 Antibody
a (U) GIA (% Inhibition)
b Change between Days 0 and 42
Day 0 Day 42 Day 0 Day 42 ELISA GIA
Recombivax 2 181 178 21 19 23 22
7 161 141 9 16 220 7
9 121 96 8 10 225 2
10 1460 1395 38 38 265 0
13 1137 943 54 50 2194 24
14 88 86 37 31 23 26
19 129 114 36 34 215 22
24 179 160 25 33 219 8
25 14 13 13 21 218
27 1143 1387 42 45 243 3
28 1023 1337 40 47 313 7
29 763 867 33 36 103 3
39 78 61 14 11 218 23
42 1003 931 42 39 272 22
43 65 159 32 29 94 24
46 2944 2858 30 17 287 214
47 32 36 12 2 4 210
51 3723 3371 55 61 2352 5
AMA1-C1 (80 mg) 37 1607 2373 40 37 766 23
38 62 577 23 25 515 2
40 750 2297 36 29 1547 27
41 156 439 20 18 283 22
44 352 733 36 35 382 21
45 53 103 42 33 50 29
48 237 302 17 5 65 212
49 423 662 25 29 238 4
50 620 1745 67 62 1125 24
52 1635 4169 21 30 2534 9
53 2579 5961 60 76 3382 16
54 1349 2573 22 23 1224 1
aThe ELISA unit values shown are the amounts of anti-AMA1 antibody in purified IgG added to test wells for the growth inhibition assay
bPercent inhibition of parasite growth compared to wells with equivalent concentrations of normal human serum
doi:10.1371/journal.pone.0001045.t003
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